Sapient Capital LLC Purchases New Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sapient Capital LLC bought a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 10,146 shares of the biotechnology company's stock, valued at approximately $978,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in SRPT. Vanguard Group Inc. boosted its position in shares of Sarepta Therapeutics by 0.5% in the third quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company's stock worth $1,039,212,000 after purchasing an additional 41,465 shares during the period. Picton Mahoney Asset Management bought a new position in shares of Sarepta Therapeutics in the third quarter worth approximately $2,576,000. WCM Investment Management LLC bought a new position in shares of Sarepta Therapeutics in the fourth quarter worth approximately $600,000. Capula Management Ltd bought a new position in shares of Sarepta Therapeutics in the third quarter worth approximately $1,409,000. Finally, State of New Jersey Common Pension Fund D boosted its position in shares of Sarepta Therapeutics by 8.2% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 51,398 shares of the biotechnology company's stock worth $4,956,000 after purchasing an additional 3,912 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Trading Up 2.3 %

Shares of Sarepta Therapeutics stock traded up $3.03 on Friday, reaching $133.66. The company had a trading volume of 1,196,284 shares, compared to its average volume of 876,130. The firm has a market cap of $12.63 billion, a price-to-earnings ratio of 1,215.09 and a beta of 0.95. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.45. The firm's 50-day moving average price is $125.63 and its two-hundred day moving average price is $110.76. Sarepta Therapeutics, Inc. has a 1 year low of $55.25 and a 1 year high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.84. The firm had revenue of $413.50 million during the quarter, compared to analysts' expectations of $375.52 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The company's quarterly revenue was up 63.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.44) EPS. As a group, research analysts predict that Sarepta Therapeutics, Inc. will post 2.23 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

SRPT has been the subject of a number of research reports. TheStreet upgraded shares of Sarepta Therapeutics from a "d" rating to a "c-" rating in a research report on Monday, March 4th. Mizuho raised their price objective on Sarepta Therapeutics from $130.00 to $145.00 and gave the company a "buy" rating in a research report on Wednesday, February 14th. Needham & Company LLC reiterated a "buy" rating and issued a $166.00 target price on shares of Sarepta Therapeutics in a research report on Thursday. JPMorgan Chase & Co. dropped their price target on Sarepta Therapeutics from $177.00 to $175.00 and set an "overweight" rating for the company in a research note on Friday. Finally, Barclays lifted their price objective on Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an "overweight" rating in a research note on Thursday, February 29th. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $160.60.

Insider Activity at Sarepta Therapeutics

In related news, insider Bilal Arif sold 2,000 shares of the business's stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the completion of the transaction, the insider now owns 26,836 shares in the company, valued at approximately $3,457,550.24. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director Kathryn Jean Boor sold 761 shares of the business's stock in a transaction on Monday, March 11th. The stock was sold at an average price of $122.93, for a total transaction of $93,549.73. Following the completion of the transaction, the director now owns 7,516 shares in the company, valued at approximately $923,941.88. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Bilal Arif sold 2,000 shares of Sarepta Therapeutics stock in a transaction on Friday, March 1st. The shares were sold at an average price of $128.84, for a total value of $257,680.00. Following the sale, the insider now directly owns 26,836 shares of the company's stock, valued at $3,457,550.24. The disclosure for this sale can be found here. Insiders sold a total of 22,096 shares of company stock worth $2,739,419 in the last quarter. 7.40% of the stock is owned by company insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.